Ketamine Troches for Social Anxiety Disorder: What the Evidence Says

Social Anxiety Disorder: More Than Shyness

Social anxiety disorder (SAD) is a persistent, intense fear of being watched, judged, or humiliated in social or performance situations. It goes well beyond ordinary nervousness. People with SAD may avoid job interviews, decline promotions that require public speaking, withdraw from friendships, or struggle with basic interactions like ordering food or making phone calls.

According to the National Institute of Mental Health, social anxiety disorder affects approximately 7 percent of American adults in any given year, making it one of the most common anxiety disorders. Despite effective treatments existing, many patients respond only partially — or not at all — to first-line therapies.

Standard Treatments and Their Limitations

First-Line Approaches

• Cognitive behavioral therapy (CBT): The most evidence-based psychotherapy for SAD. Involves gradual exposure to feared social situations combined with cognitive restructuring. Effective for many patients but requires sustained engagement and access to a trained therapist.
• SSRIs and SNRIs: Sertraline (Zoloft), paroxetine (Paxil), and venlafaxine (Effexor) are FDA-approved for SAD. They help approximately 50 to 60 percent of patients but often produce only partial symptom improvement.
• Combination therapy: CBT plus medication produces better outcomes than either alone.

Treatment-Resistant Social Anxiety

A significant proportion of patients — estimated at 30 to 40 percent — do not achieve adequate symptom relief from standard treatments. These patients may have tried multiple SSRIs, therapy modalities, and adjunctive medications (benzodiazepines, buspirone, beta-blockers) without sufficient improvement. For this group, novel approaches including ketamine are increasingly being explored.

How Ketamine May Help Social Anxiety

Ketamine's mechanisms of action align with several key aspects of social anxiety neurobiology:

NMDA Receptor Modulation and Glutamate

Social anxiety disorder involves dysregulated glutamate signaling in brain regions responsible for threat processing, including the amygdala and prefrontal cortex. NMDA receptors in these areas help encode and maintain fear memories — including the conditioned fear responses that drive social avoidance.

By blocking NMDA receptors, ketamine disrupts the maintenance of maladaptive fear memories and may create a window during which these memories can be reconsolidated in a less distressing form. This is the same mechanism that underlies ketamine's potential in PTSD.

Neuroplasticity Enhancement

Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis — the formation of new synaptic connections — in the prefrontal cortex. In social anxiety, the prefrontal cortex often fails to adequately regulate the amygdala's threat response. Enhancing prefrontal connectivity may restore top-down control over fear circuits.

This neuroplasticity effect is thought to be why ketamine's benefits often outlast its presence in the body. The new synaptic connections persist after the drug is metabolized, potentially providing a lasting change in how the brain processes social threat signals.

Fear Extinction

Laboratory research has shown that ketamine facilitates fear extinction — the process by which learned fear responses are weakened through repeated safe exposure. For social anxiety, this is particularly relevant because the core pathology is an overlearned fear response to social situations. If ketamine enhances the brain's ability to "unlearn" these fear responses, it could accelerate the work done in exposure-based therapy.

Rapid Mood and Anxiety Reduction

Many patients with social anxiety also experience comorbid depression and generalized anxiety. Ketamine's rapid antidepressant and anxiolytic effects — often noticeable within hours to days of the first session — can provide relief that makes it easier to engage in therapy and social exposure.

What the Research Shows

Clinical Evidence for Ketamine and Anxiety

Research on ketamine specifically for social anxiety disorder is still in early stages, but related evidence is encouraging:

• A 2018 randomized controlled trial published in the American Journal of Psychiatry found that IV ketamine significantly reduced anxiety symptoms in patients with treatment-resistant anxiety disorders (including SAD and generalized anxiety disorder). Improvement was evident within hours and lasted up to 2 weeks after a single infusion.
• A 2017 crossover trial in Neuropsychopharmacology demonstrated that ketamine reduced anxiety symptoms in patients with comorbid depression and anxiety, with effects persisting for up to 14 days.
• Observational studies from ketamine clinics consistently report that patients with comorbid anxiety experience significant anxiety reduction alongside mood improvement.
• Sublingual ketamine studies have shown similar anxiolytic effects to IV ketamine, though with somewhat slower onset due to the absorption profile of troches.

Limitations of Current Evidence

Important caveats:

• Most studies have focused on generalized anxiety symptoms rather than the specific social fear pattern of SAD
• Sample sizes have been small
• Long-term outcome data for ketamine in anxiety disorders is limited
• The optimal dosing protocol for anxiety (vs. depression) has not been established
• No studies have specifically examined at-home sublingual ketamine troches for social anxiety as a primary indication

The evidence is promising but preliminary. Ketamine for social anxiety is an off-label use that is less well-studied than ketamine for depression.

How Troches Might Be Used for Social Anxiety

Treatment Protocols

Providers who prescribe troches for social anxiety typically use one of these approaches:

Standalone treatment for refractory SAD: Regular troche sessions (2 to 3 times per week) aimed at reducing baseline anxiety levels and improving social functioning. This approach is reserved for patients who have failed adequate trials of SSRIs and CBT. Doses are generally similar to those used for depression — starting at the provider's recommended initial dose and adjusting based on response, as outlined in the titration guide.

Ketamine-assisted psychotherapy: Troches used in conjunction with therapy sessions, leveraging ketamine's neuroplasticity window to enhance the effectiveness of exposure-based or cognitive therapy. In this model, a therapy session may occur during or shortly after the troche experience, while the brain is in a heightened state of plasticity. This is a specialized approach that requires coordination between the prescriber and therapist.

Adjunctive treatment: Troches used alongside existing SSRI treatment and therapy, providing additional anxiolytic benefit for patients with partial response to standard care.

Dosing Considerations for Anxiety

Some providers observe that social anxiety responds to lower doses of ketamine than treatment-resistant depression:

• Starting doses of 50 to 100 mg are common
• Some patients achieve meaningful anxiety reduction at doses that produce minimal dissociation
• Higher doses are not necessarily better for anxiety — in fact, very high doses can temporarily increase anxiety in some patients due to the intensity of the dissociative experience
• Dose adjustment should be guided by your response and your provider's experience — see what dose should I start with

The Role of Integration and Therapy

Ketamine alone is unlikely to fully resolve social anxiety. The drug may reduce the neurobiological drivers of fear — lowering the "volume" on threat signals from the amygdala and enhancing prefrontal regulation — but behavioral change still requires active engagement.

This is where integration practices become especially important:

• Post-session reflection: After each troche session, spend time reflecting on social situations that trigger anxiety. Many patients report that ketamine temporarily reduces the emotional charge of feared scenarios, making it possible to think about them more objectively.
• Gradual social exposure: Use the window of reduced anxiety following sessions to practice social interactions that would normally be avoided. Start small — a phone call, a conversation with a neighbor, attending a small gathering.
• Therapy alignment: If you are in CBT or another therapy for social anxiety, coordinate session timing with your therapist. Some patients find that therapy sessions scheduled within 24 to 48 hours of a troche session are particularly productive.
• Journaling: Track not only your dose and session quality but also your social behavior between sessions. Are you avoiding less? Engaging more? These behavioral markers may be more meaningful than subjective anxiety ratings.

Who Might Benefit Most

Ketamine troches for social anxiety are most commonly considered for patients who:

• Have moderate to severe SAD that significantly impairs work, relationships, or daily functioning
• Have tried at least two adequate trials of SSRIs or SNRIs (typically 8 to 12 weeks at therapeutic doses)
• Have engaged in CBT or exposure therapy without sufficient improvement
• Do not have contraindications to ketamine
• Are willing to combine troche use with ongoing therapy or structured social exposure
• Have comorbid depression that could also benefit from ketamine treatment

Ketamine is not a first-line treatment for social anxiety. It is a tool for patients who have not responded adequately to established treatments.

What to Expect

Patients using troches for social anxiety commonly report:

• Within the first 1 to 3 sessions: A sense of emotional distance from social fears. Not that the fears disappear, but that they feel less urgent and all-consuming.
• Over 2 to 4 weeks: Gradual improvement in willingness to engage in social situations. Reduced anticipatory anxiety before social events.
• Over 1 to 3 months: Measurable improvement in social functioning — accepting invitations, participating in meetings, initiating conversations.
• Ongoing: Continued improvement as long as troche use is maintained alongside behavioral engagement. Some patients are able to reduce session frequency over time as gains consolidate.

Not all patients respond, and response is not always dramatic. A realistic expectation is meaningful improvement in anxiety symptoms and social functioning, not complete elimination of anxiety.

Safety and Monitoring

The general safety profile and monitoring guidelines for ketamine troches apply. Specific considerations for social anxiety patients:

• Benzodiazepine interactions: Many SAD patients take benzodiazepines (clonazepam, alprazolam) for acute anxiety. Benzodiazepines may reduce ketamine's therapeutic effects and add sedation risk. Discuss the interaction with your provider and review the drug interactions guide.
• Avoidance patterns: Some patients may use troche sessions as a way to avoid social situations (retreating into the session experience rather than engaging with life). A good provider will monitor for this pattern.
• Alcohol use: Social anxiety and alcohol use are commonly comorbid. Alcohol must not be combined with ketamine — see troches and alcohol.

Finding a Provider

When seeking a prescriber for social anxiety treatment with troches, look for providers who:

• Have experience treating anxiety disorders (not only depression) with ketamine
• Understand the distinction between social anxiety and generalized anxiety
• Value integration and therapy alongside medication
• Can coordinate with your existing therapist if applicable

The finding a prescriber and questions to ask guides can help you evaluate potential providers.

References

• Glue P, et al. Ketamine's Dose-Related Effects on Anxiety Symptoms in Patients With Treatment Refractory Anxiety Disorders. Journal of Psychopharmacology, 2018 — Dose-response study of ketamine for anxiety
• Taylor JH, et al. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology, 2018 — RCT examining ketamine for anxiety disorders
• National Institute of Mental Health: Social Anxiety Disorder — Epidemiological and clinical overview
• Mayo Clinic: Social Anxiety Disorder — Patient-facing overview of SAD
• Duman RS, Aghajanian GK. Synaptic Dysfunction in Depression: Potential Therapeutic Targets. Science, 2012 — Foundational research on ketamine's neuroplasticity mechanisms
• WHO: Depression and Other Common Mental Disorders — Global burden data including anxiety disorders